Medroxyprogesteronacetat als Glucocorticoid in der Kombination mit Aminoglutethimid zur Therapie des metastasierenden Mammakarzinoms

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Eine wesentliche Wirkung des Medroxyprogesteronacetats ist die intrinsische glucocorticoidartige Aktivität. Bei der Therapie des metastasierenden Mammakarzinoms mit hochdosiertem MAP konnte die cortisolartige Wirkung des MAP auch im Rahmen einer Langzeittherapie nachgewiesen werden. MAP supprimiert über die zentrale ACTH-Hemmung die endogene Cortisolsekretion. Die cortisolartige Wirkung in holier Dosierung reicht aus, um die obligate Cortisolsubstitution bei der Therapie mit Aminoglutethimid zu ersetzen. Dies ermöglicht die Kombination zweier endokrin wirksamer Pharmaka in der Therapie des metastasierenden Mammakarzinoms.

Related collections

Author and article information

Journal

Journal ID (publisher-id): ONK

Journal ID (nlm-ta): Oncol Res Treat

Journal ID (doi): 10.1159/issn.2296-5270

Title: Oncology Research and Treatment

Publisher: S. Karger AG

ISBN: 978-3-8055-3643-1

ISBN: 978-3-318-05758-4

ISSN (Print): 2296-5270

ISSN (Electronic): 2296-5262

Publication date Subscription-year: 1982

Publication date (Print): 1982

Publication date (Electronic): 21 April 2009

Volume: 5

Issue: Suppl 1

Pages: 26-30

Affiliations

^aZentrum für Innere Medizin, Abteilung Endokrinologie, Göttingen ^bZentrum für Innere Medizin, Abteilung Hämatologie/Onkologie, Göttingen ^c Hamburg

Article

Publisher ID: 215037 Other ID: Onkologie 1982;5:26–30

DOI: 10.1159/000215037

SO-VID: 0d0397dd-6e7c-4b4c-b6db-62bf9a05c79d

License:

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Call for Papers: Supportive Care - Essential for Modern Oncology

Submit here before December 31, 2024

Medroxyprogesteronacetat als Glucocorticoid in der Kombination mit Aminoglutethimid zur Therapie des metastasierenden Mammakarzinoms

Read this article at

Abstract

Related collections

Karger: Oncology

Author and article information

Journal

Affiliations

Article

History

Page count

Categories

Comments

Comment on this article

Similar content 520